The British Journal of Cardiology

This site is intended for UK healthcare professionals

Sponsorship statement:
Novartis Pharmaceuticals UK Ltd has provided OmniaMed Communications Ltd with an arm’s length sponsorship towards the development of the British Journal of Cardiology Masterclasses.

Masterclass: Lipids – Non-statin approaches to treatment

5 March 2024
Available for 1 CPD point(s)


Watch Dr Rani Khatib and Dr Dermot Neely delve into non-statin lipid-lowering therapies in cardiovascular disease, including when they should be used and in which groups of patients.

Dr Rani Khatib Consultant Pharmacist in Cardiology & Cardiovascular Research, Leeds Teaching Hospitals NHS Trust
Dr Dermot Neely Specialist Adviser on lipids to Academic Health Science Network – North-East and North Cumbria

Learning objectives

    • Understand the national lipid management pathway, and primary and secondary prevention of cardiovascular disease

    • Understand when non-statin therapeutic approaches may be indicated in clinical practice

    • Identify the patient groups who may benefit from non-statin lipid-lowering therapeutic options

    Learning module instructions

    This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.

    1. NHS England. Improving lipid management to reduce cardiovascular disease and save lives. 2023. Available at: (accessed February 2024)
    2. NICE. CKS. Lipid modification – CVD prevention: Statins. 2023. Available at: (accessed February 2024)
    3. NHS England. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD. Available at: (accessed February 2024)
    4. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. December 2023. Available at: (accessed February 2024)

    Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.